文献速递类风湿关节炎

羟氯喹用于类风湿关节炎高危人群的2期试验

A Phase 2 Trial of Hydroxychloroquine in Individuals at Risk for Rheumatoid Arthritis.
PubMed 文献 · Arthritis Rheumatol · 2026-03-16

这项2期随机试验纳入抗环瓜氨酸肽(anti-CCP)抗体3型≥2倍正常上限的类风湿关节炎高危个体,随机接受羟氯喹或安慰剂治疗12个月并随访至36个月。36个月时临床类风湿关节炎发生风险羟氯喹组为0.336、安慰剂组为0.394,差异无统计学意义(P=0.52),不良事件发生率两组相似。

要点

  • 抗CCP3≥2倍正常上限的类风湿关节炎高危个体中,12个月羟氯喹未预防36个月临床类风湿关节炎发生。
  • 36个月临床类风湿关节炎风险羟氯喹组0.336 vs 安慰剂组0.394,差异-0.058(95%CI -0.336至0.220;P=0.52)。
  • 炎症性关节炎结果相似,关节症状发生与严重程度两组未见差异,不良事件发生率相似。

核心结论

  • 在抗CCP3≥2倍正常上限的类风湿关节炎高危个体中,12个月羟氯喹未预防36个月时临床类风湿关节炎的发生。

研究设计与样本

  • 2期随机试验,纳入抗CCP3≥2倍正常上限的类风湿关节炎高危个体,羟氯喹组71例、安慰剂组73例,共144例随机分组。
  • 干预为羟氯喹或安慰剂治疗12个月,停药后随访至24个月,主要结局为36个月时方案定义的临床类风湿关节炎。

主要发现

  • 改良意向治疗人群中,临床类风湿关节炎发生于羟氯喹组69例中的21例(30.4%)和安慰剂组73例中的24例(32.9%)。
  • 36个月临床类风湿关节炎风险羟氯喹组0.336 vs 安慰剂组0.394,差异-0.058(95%CI -0.336至0.220;P=0.52)。
  • 炎症性关节炎结果相似,参与者报告的关节症状发生与严重程度两组未见差异,不良事件发生率两组相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Individuals with serum elevations of anti-cyclic citrullinated peptide (anti-CCP) antibodies are at increased risk for future rheumatoid arthritis (RA). No pharmacologic interventions have been approved for the prevention of RA in such at-risk individuals. However, hydroxychloroquine (HCQ) is used without supporting clinical trial evidence. METHODS: In this phase 2 randomized trial, individuals at risk for RA with anti-CCP3 ≥2 times the upper limit of normal (ULN) were assigned to receive HCQ or placebo for 12 months, with up to 24 months of postdrug follow-up. The primary outcome was the development of clinical RA, as defined in the protocol, at 36 months. Secondary outcomes included safety, development of inflammatory arthritis (IA), and participant-reported joint symptoms. RESULTS: Of 144 randomized participants, 71 were assigned to HCQ and 73 to placebo. In the modified intent-to-treat population, clinical RA occurred in 21 of 69 (30.4%) participants in the HCQ group and 24 of 73 (32.9%) in the placebo group. The risk of clinical RA at 36 months was 0.336 with HCQ and 0.394 with placebo (difference -0.058; 95% confidence interval -0.336 to 0.220; P = 0.52). Results for IA were similar. The occurrence and severity of joint symptoms were not observed to differ between groups. Adverse event incidence was similar between groups. CONCLUSION: In this trial involving individuals with anti-CCP3 levels ≥2 times the ULN, 12 months of HCQ did not prevent the development of clinical RA at 36 months.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Deane KD, Striebich CC, Feser ML, et al. A Phase 2 Trial of Hydroxychloroquine in Individuals at Risk for Rheumatoid Arthritis. Arthritis Rheumatol. 2026. PMID: 40884017. doi:10.1002/art.43366

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。